Reata Pharmaceuticals Inc buy Heureka
Summary
This prediction ended on 04.02.20 with a price of €220.00. The BUY prediction by Heureka finished with a performance of 17.02%. Heureka has 50% into this predictionReata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on identifying, developing, and commercializing novel therapeutics for patients with severe and life-threatening diseases. The company's primary business areas include drug discovery and development in fields such as cardiovascular, fibrotic, mitochondrial, and neurodegenerative diseases. With a strong emphasis on research and innovation, Reata Pharmaceuticals seeks to deliver cutting-edge treatments that address unmet medical needs, improve patient outcomes, and significantly impact the lives of those suffering from rare and debilitating conditions. As a publicly traded company, Reata Pharmaceuticals is listed on the NASDAQ stock exchange under the ticker symbol "RETA."
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Reata Pharmaceuticals Inc | - | - | - | - |
| iShares Core DAX® | 0.170% | 2.184% | 15.013% | 60.946% |
| iShares Nasdaq 100 | 0.515% | 0.370% | 6.226% | 96.569% |
| iShares Nikkei 225® | 1.614% | 6.357% | 21.242% | 50.975% |
| iShares S&P 500 | -0.719% | -0.275% | 1.451% | 61.446% |
Comments by Heureka for this prediction
In the thread Reata Pharmaceuticals Inc diskutieren